CoChat

Interleukin 10 Treatment of Psoriasis: Clinical Results of a Phase 2 Trial

Asadullah, Khusru, Döcke, Wolf-Dietrich, Ebeling, Merle, Friedrich, Markus, Belbe, Gudrun, Audring, Heike, Volk, Hans-Dieter, Sterry, Wolfram · 1999 · Archives of Dermatology
Cited by 151

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To determine the safety and clinical effects of interleukin 10 (IL-10) treatment of psoriasis. DESIGN AND METHODS: In an open-label phase 2 trial, 10 patients with psoriasis subcutaneously received recombinant human IL-10 over a 7-week period in a dosage of 8 microg/kg daily (n=5) or 20 microg/kg 3 times per week (n=5). Patients were followed up for an additional 5 weeks. RESULTS: The treatment was well tolerated. Antipsoriatic effects were found in all but 1 patient. A significant decrease of the psoriasis area and severity index by 55.3% +/- 11.5% (mean +/- SEM) was observed (P<.02). The antipsoriatic efficiency was confirmed by histological examination. Heterogeneity in the effectiveness was found among the patients, but seems to be independent of the dosage regimen. However, a tendency to a better response was found in the patients who received 20-microg/kg IL-10 3 times per week. Decreasing response in the delayed-type hypersensitivity reaction against recall antigens indicated immunosuppressive effects. Moderate effects on hematopoietic cells were observed. CONCLUSIONS: Our data suggest that IL-10 therapy for psoriasis is safe and possibly clinically effective. Consequently, its value in psoriasis and similar immune diseases should be further determined. Dose-finding, placebo-controlled, double-blind trials are necessary now.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/archderm.135.2.187

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 151

Metadata

Authors
Asadullah, K., Döcke, W.-D., Ebeling, M., Friedrich, M., Belbe, G., Audring, H., Volk, H.-D., & Sterry, W.
Venue
Archives of Dermatology
Published
1999-02-01
Volume
135
Issue
2
Pages
187-92
ISSN
0003-987X (ISSN-L)
OpenAlex
W1999202157
Cited by
151
References
3
FWCI
5.23
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Interleukin 10 Treatment of Psoriasis: Clinical Results of a Phase 2 Trial. https://app.cochat.ai/papers/10.1001/archderm.135.2.187
The paper
Asadullah, K., Döcke, W.-D., Ebeling, M., Friedrich, M., Belbe, G., Audring, H., Volk, H.-D., & Sterry, W. (1999). Interleukin 10 Treatment of Psoriasis: Clinical Results of a Phase 2 Trial. Archives of Dermatology. https://doi.org/10.1001/archderm.135.2.187

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.